Table 2.

Baseline characteristics

CasesAll (n = 54)Control (n = 27)Intervention (n = 27)
Age (year)10.8 ± 4.211.3 ± 4.310.2 ± 4.0
Body weight (kg)42.6 ± 17.545.5 ± 19.339.6 ± 15.2
Men43 (79.6)19 (70.4)24 (88.9)
Disease duration (years)6.7 ± 3.97.8 ± 4.05.7 ± 3.5
Renal histology
    Unavailable18 (33.3)11 (40.7)7 (25.9)
    FSGS17 (31.5)10 (37.1)7 (25.9)
    MCD19 (35.2)6 (22.2)13 (48.1)
Steroid toxicity19 (35.1)9 (33.3)10 (37.0)
CNI toxicity5 (9.2)3 (11.1)2 (7.4)
CTX therapy31 (57.4)13 (48.1)18 (66.7)
Prednisone (mg/kg per day)0.58 ± 0.440.60 ± 0.470.57 ± 0.42
CsA/FK506a38 (70)/16 (30)19 (70)/8 (30)19 (70)/8 (30)
ARB/ACEI25 (46.3)15 (55.5)10 (37.1)
Urinary protein (g/d)1.6 ± 2.81.6 ± 2.11.6 ± 3.4
Serum albumin (g/dl)3.4 ± 0.93.2 ± 0.83.6 ± 0.9
Serum cholesterol (mg/dl)276 ± 161283 ± 116268 ± 200
Serum creatinine (mg/dl)0.55 ± 0.20.55 ± 0.20.55 ± 0.3
White blood cells (μl−1)10,534 ± 4,15010,703 ± 4,12110,365 ± 4,250
IgG (g/dl)533 ± 267488 ± 265575 ± 268
  • Mean ± SD reported for quantitative variables (unit) and absolute (%) for qualitative variables. FSGS, focal and segmental glomerular sclerosis; MCD, minimal change disease; CNI, calcineurin inhibitors (cyclosporine or tacrolimus) used at full dose (necessary to maintain trough levels of 50 to 100 ng/ml for cyclosporine [CsA] and 5 to 10 ng/ml for tacrolimus [FK506]); CTX therapy, previous use of cytotoxic agents (Endoxan, Leukeran).

  • a In two patients, CsA was stopped during the run-in for severe toxicity.